Edwards Lifesciences: A Promising Investment in Structural Heart Therapies

Edwards Lifesciences Corporation (EW) has emerged as a leading player in the structural heart therapies market, with a strong focus on innovative technologies and a robust pipeline. As the company enters its first full year as a purely structural heart company in 2025, investors may be wondering if the growth prospects of EW are worth considering. This article explores the key growth drivers, innovative technologies, and future opportunities that make EW an attractive investment option.



Key Growth Drivers

1. Transcatheter Aortic Valve Replacement (TAVR): EW's TAVR is positioned for strong sustainable growth, driven by greater awareness, patient access, advances in new technologies, indication expansion, and increased global adoption. The company's SAPIEN platform of TAVR valves remains the category leader and the best-in-class therapy for lifetime management of aortic stenosis. Upcoming milestones include the strong global adoption of the SAPIEN 3 Ultra RESILIA system, the transformation of patient care stemming from the EARLY TAVR pivotal trial, and the advancement through the follow-up process of the PROGRESS pivotal trial.
2. Transcatheter Mitral and Tricuspid Therapies (TMTT): EW is revolutionizing care for millions of patients suffering from mitral and tricuspid valve diseases. The company has successfully commercialized a unique portfolio of differentiated therapies, including PASCAL and EVOQUE, and remains committed to its strategy of transformative product innovation, robust and expanding clinical evidence to support approvals and adoption, and comprehensive support to ensure excellent real-world patient outcomes. Upcoming milestones include the commercialization in the U.S. and Europe of the EVOQUE tricuspid valve, the continued global expansion of the PASCAL Precision system, and the CE Mark for SAPIEN M3, the world's first transcatheter mitral valve replacement system.
3. Surgical Structural Heart: EW remains committed to advancing its leadership in surgical structural heart therapies. The company is focused on identifying and solving critical unmet needs in cardiac surgery to help patients live longer, healthier, and more active lives. In 2025, EW expects to continue driving the adoption of its flagship surgical aortic heart valve, INSPIRIS RESILIA, and accelerate its surgical mitral valve leadership with the global commercialization of its MITRIS RESILIA valve.
4. Future opportunities with Structural Heart Failure and Aortic Regurgitation (AR): EW sees increasing contributions from new therapeutic areas, including Structural Heart Failure and AR, as significant patient opportunities. These areas have the potential to drive strong total company sales growth and double-digit EPS growth in the long term.



Innovative Technologies

EW's innovative technologies, such as RESILIA, play a significant role in driving growth by addressing critical unmet needs in cardiac surgery and helping patients live longer, healthier, and more active lives. The company's commitment to identifying and solving these unmet needs is evident in its focus on advancing its leadership in surgical structural heart therapies.

One of the key examples of EW's innovative technologies is the INSPIRIS RESILIA surgical aortic heart valve, which is changing the standards of tissue durability in cardiac surgery. This valve is designed to provide enhanced durability and improved patient outcomes, making it a valuable addition to the company's portfolio of premium RESILIA technologies.

Another example is the MITRIS RESILIA valve, which is expected to accelerate EW's surgical mitral valve leadership. This valve is designed to address the specific needs of patients with mitral valve disease, offering a unique combination of durability, performance, and ease of use.

By investing in groundbreaking trials and research and development, EW is committed to helping more patients and further strengthening its long-term leadership position in the structural heart market. The company's focus on innovation and addressing unmet needs is a key driver of its growth and success.

Future Opportunities

EW's growth prospects are further enhanced by its focus on indication expansion and new therapeutic areas. The company is actively pursuing indication expansion for its TAVR and TMTT therapies, as well as exploring new therapeutic areas such as Structural Heart Failure and AR. These efforts can open up new markets and drive additional growth.

In conclusion, Edwards Lifesciences Corporation (EW) offers a compelling investment opportunity for those seeking exposure to the growing structural heart therapies market. With its strong focus on innovative technologies, robust pipeline, and promising growth prospects, EW is well-positioned to deliver long-term value for investors. As the company enters its first full year as a purely structural heart company in 2025, investors should consider the key growth drivers, innovative technologies, and future opportunities that make EW an attractive investment option.